New drugs for the treatment of type 2 diabetes

Br J Hosp Med (Lond). 2007 Apr;68(4):178-83. doi: 10.12968/hmed.2007.68.4.178.

Abstract

Insights into the pathogenesis of type 2 diabetes has led to increasing therapeutic targets for intervention, and improvements in peptide delivery technology have lead to non-injection methods of insulin delivery. This article reviews new drugs which are likely to become available for use by people with diabetes over the coming year.

Publication types

  • Review

MeSH terms

  • Adenosine Deaminase Inhibitors
  • Administration, Inhalation
  • Amyloid
  • Cannabinoid Receptor Antagonists
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Dipeptidyl Peptidase 4
  • Dipeptidyl-Peptidase IV Inhibitors
  • Forecasting
  • Glucagon-Like Peptide 1 / antagonists & inhibitors
  • Glycoproteins / antagonists & inhibitors
  • Humans
  • Hypoglycemic Agents / therapeutic use*
  • Insulin / administration & dosage
  • Islet Amyloid Polypeptide
  • Technology, Pharmaceutical / trends*

Substances

  • Adenosine Deaminase Inhibitors
  • Amyloid
  • Cannabinoid Receptor Antagonists
  • Dipeptidyl-Peptidase IV Inhibitors
  • Glycoproteins
  • Hypoglycemic Agents
  • Insulin
  • Islet Amyloid Polypeptide
  • Glucagon-Like Peptide 1
  • DPP4 protein, human
  • Dipeptidyl Peptidase 4